1 Ozark Health Ventures, LLC d/b/a Cancer Research for the Ozarks (CRO) is submitting 2 this grant application as it desires to continue to be involved with the cooperative efforts 3 of the NCI Community Oncology Research Program (NCORP) to focus on the broader 4 needs of cancer prevention and treatment, cancer care delivery, imaging studies and 5 cancer disparities. 6 Cancer Research for the Ozarks has a long and mutually beneficial history with the NCI 7 for over 31 years of offering clinical trial access to rural communities within the central 8 United States. Since its inception, CRO has grown from southwest Missouri, to 9 increasing its network to 15 component sites that incorporate 42 counties in five states 10 with a predominately rural population of more than 4,300,000. CRO would be the 11 primary access for NCI-sponsored and NTCN network trials for the vast majority of these 12 patients. The population in CRO?s catchment area is generally Caucasian, and slightly 13 older and poorer than national averages. CRO has been a significant contributor to 14 enrollments in protocols involving cancer prevention and treatment, cancer care delivery, 15 imaging studies, and cancer disparities. CRO has also had numerous registrations to 16 cancer care delivery and tissue procurement protocols. CRO routinely meets the NCI 17 criteria for enrollments and for the number of CCDR protocols it has open. CRO has a 18 plan for further expansion of components and investigators to secure even higher 19 enrollments. CRO participates with the following research bases: Alliance: member since 20 June, 2012; NRG: member since their merger in 2014 and the preceding legacy groups; 21 SWOG: member since its inception in 1987; Wake Forest: member since their inception 22 in 2014 and participated in protocols with the preceding Cancer Center; ECOG-ACRIN: 23 member since 2014 and the preceding legacy groups. In addition, CRO has been 24 involved in the Children?s Oncology Group at Mercy St. Louis since June 2011. The 25 major collective strengths of the CRO application would be the tremendous support and 26 commitment of the two primary components, the broad network of component sites, the 27 quality, integrity and experience of CRO?s leadership and the program, and the many 28 investigators and collaborators that it supports. 29

Public Health Relevance

Cancer Research for the Ozarks, though this NCORP grant, will continue to be the primary access to NCI sponsored research for the poor, rural patients across 42 counties in its five state catchment area. This access is critical to providing these patients with cutting edge, quality cancer treatment, prevention, and care delivery research in their local communities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189822-07
Application #
9996499
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Lee, Cecilia H
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ozark Health Ventures, LLC
Department
Type
DUNS #
808197565
City
Springfield
State
MO
Country
United States
Zip Code
65804
Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Wagner, Lynne I; Zhao, Fengmin; Goss, Paul E et al. (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG Breast Cancer Res Treat 169:537-548
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chan, John K; Deng, Wei; Higgins, Robert V et al. (2017) A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 146:554-559
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522

Showing the most recent 10 out of 16 publications